Study: Millions of people with diabetes won’t get the insulin they need by 2030

woman doing injection

Stanford researchers this week released a sobering study that predicts about 40 million people around the world won’t be able to get the insulin they need for their diabetes in 12 years’ time — if trends continue.

The modelling study, led by Dr. Sanjay Basu, MD, PhD, of Stanford’s Center for Health Policy, was published November 19th in The Lancet Diabetes & Endocrinology. The university released a press release and a number of news outlets also covered the story.

The Lancet: Insulin shortage could affect 40 million people with type 2 diabetes

CNN: Diabetes: 40 million people will be left without insulin by 2030

MedPage Today: What will global insulin use look like by 2030?

Using data from 221 countries, the researchers modelled various scenarios and estimated that by 2030 the number of people with diabetes worldwide will rise by 20%, from 406 million up to 511 million. The United States will have the third highest numbers, with an expected 32 million people with diabetes in 12 years.

Of those with type 2 diabetes, about 15.5% — some 79 million people globally — are expected to require insulin to keep their blood glucose in check. However, the study projects that without major improvements in the cost and access to insulin, almost half of those — some 40 million people — will not be able to get it. The impact is predicted to be greatest in Africa and Asia.

Basu and his co-authors warn that strategies must be adopted to make insulin more widely available and affordable. Insulin is expensive and the market is currently dominated by just three manufacturers, they noted.

One strategy that they modelled was to relax the guidelines for blood sugar targets for diabetics over the age of 75. Rather than aim for current HbA1C targets of 6.5 to 7%, aiming instead for 8% in older people “would halve the need for insulin” and better balance the health risks and benefits to those affected.

Basu and his team, however, did not model the impact of a widespread change in diet and lifestyle, which they noted was one of the limitations of their study.

How might a significant global uptake of low-carb ketogenic diets, which helps prevent and reverse diabetes, impact insulin needs?

Their study can’t say. However, the results of the 1-year Virta Health clinical trial, released earlier this year, gives some promising clues. The Virta study found that an impressive 94% of their diabetic participants who followed the low-carb ketogenic diet reduced or completely eliminated their use of insulin.

Anne Mullens


$150 million for diabetes strategy in Canada

Diabetes defeated by diet

Type 2 diabetes rises dramatically among young people

Low carb


  1. Kenrick
    Yes and how sad the excellent work carried out by Virtua Clinic doesn’t seem to even get a 3 page by line in the media ...

    Yet look at the anti-carb / anti-fat crap that hits the headlines almost weekly - I wonder where the money is ??


  2. Catheryn
    Yes, well, I think the impetus for change is not going to come from the healthcare or the pharmacy industries, sadly. It will ultimately be driven by the health insurance and life insurance companies. Maybe then governments, who don't want to be bankrupted by the diabetes tsunami, will start paying attention.
  3. Jaine Vaughn
    As I said to a diabetic friend whose endocrinologist “almost had a heart attack” when she mentioned keto, why would he want to CURE his patients and eliminate his source of income. What happened to “first do no harm?”

Leave a reply

Reply to comment #0 by

Older posts